For example, the tumor-associated macrophages (TAMs) could be engineered to directly attack tumor cells by inhibiting SHP substrate 1 (Alvey et al., 2017), or spare the T Cell from exhaustion by losing TAM antigen presentation in an IRF8-dependent manner (Nixon et al., 2022). Here, IRF8 is linked to neoplasm.